natgillin/translations-raw huggingface dataset:
Gastrointestinal blødning, peritonitis, ileus, colitis, mavesår, ulcus duodeni, gastritis, oesophagitis, stomatitis, obstipation, dyspepsi, flatulens, opstød
Vomiting, abdominal pain, diarrhoea, nausea Gastrointestinal haemorrhage, peritonitis, ileus, colitis, gastric ulcer, duodenal ulcer, gastritis, oesophagitis, stomatitis, constipation, dyspepsia, flatulence, eructation
Hud og subkutane væv
Renal and urinary disorders Skin and subcutaneous tissue disorders
- Hud hypertrofi, udslæt, acne, alopeci
- Renal impairment - Skin hypertrophy, rash, acne, alopecia
-
- Arthralgia
bindevæv Metabolisme og ernæring
21
Almindelig Meget almindelig Almindelig
System organ class
Infektioner og parasitære sygdomme
Frequency
Meget almindelig
Adverse drug reactions
Sepsis, gastrointestinal candidiasis, urinvejsinfektioner, Herpes simplex, herpes zoster
Metabolism and nutrition disorders
Pneumoni, influenza, infektion i luftrøret, respiratorisk moniliasis, gastrointestinal infektion, candidiasis, gastroenteritis, infektion, bronkitis, pharyngitis, sinuitis, svampeinfektion i huden, hud candidiasis, vaginal candidiasis, rhinitis
- Acidosis, hyperkalaemia, hypokalaemia, hyperglycaemia, hypomagnesaemia, hypocalcaemia, hypercholesterolaemia, hyperlipidaemia, hypophosphataemia, hyperuricaemia, gout, anorexia
Benigne, maligne og uspecificerede
Infections and infestations
-
Sepsis, gastrointestinal candidiasis, urinary tract infection, herpes simplex, herpes zoster Pneumonia, influenza, respiratory tract infection, respiratory moniliasis, gastrointestinal infection, candidiasis, gastroenteritis, infection, bronchitis, pharyngitis, sinusitis, fungal skin infection, skin candida, vaginal candidiasis, rhinitis
Vaskulære sygdomme
Vascular disorders General disorders and administration site conditions
- Hypotension, hypertension, vasodilatation
- Hypotension, hypertension, vasodilatation - Oedema, pyrexia, chills, pain, malaise, asthenia
- Hepatitis, icterus, hyperbilirubinæmi
Hepatobiliary disorders Psychiatric disorders
- Agitation, konfusion, depression, angst, abnorm tankevirksomhed, insomnia
- Hepatitis, jaundice, hyperbilirubinaemia - Agitation, confusional state, depression, anxiety, thinking abnormal, insomnia
20 Note:
Note:
Sygdomme relateret til immunsuppression: alvorlige livstruende infektioner inklusive meningitis, endocarditis, tuberkulose og atypisk mycobakteriel infektion..
Disorders related to immunosuppression: serious life-threatening infections including meningitis, endocarditis, tuberculosis and atypical mycobacterial infection.
4. 4).
Agranulocytosis (uncommon) and neutropenia have been reported; therefore regular monitoring of patients taking Mycophenolate mofetil Teva is advised (see section 4.4).
Der har været indberetninger om aplastisk anæmi og knoglemarvsdepression hos patienter behandlet med mycophenolatmofetil, hvor nogle har været fatale.
There have been reports of aplastic anaemia and bone marrow depression in patients treated with mycophenolate, some of which have been fatal.
Hypersensitive reaktioner, herunder angioneurotisk ødem og anafylaktiske reaktioner, er blevet rapporteret.
22 Hypersensitivity: hypersensitivity reactions, including angioneurotic oedema and anaphylactic reaction have been reported.
4. 4).
If neutropenia develops, dosing with Mycophenolate mofetil Teva should be interrupted or the dose reduced (see section 4.4).
Mycophenolatmofetil er 2- morpholinoethyl- esteren af mycophenolsyre (MPA).
Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA).
MPA er en potent, selektiv, ikke- kompetitiv og reversibel inhibitor af inosin- monophosfat- dehydrogenase og hæmmer derfor de novo vejen for en guanosin- nucleotid - syntese uden inkorporering i DNA.
MPA is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA.
40% er associeret til den samtidige administration af colestyramin (4 g tre gange daglig), hvilket indikerer, at der er en betragtelig enterohepatisk recirkulation.
A reduction in the AUC of MPA of approximately 40% is associated with the co-administration of cholestyramine (4 g TID), indicating that these is a significant amount of enterohepatic recirculation.
Ubetydelige mængder af stoffet udskilles som MPA (< 1% af dosis) i urinen.
23 A negligible amount of substance is excreted as MPA (< 1% of dose) in the urine.
Ved høje MPAG - koncentrationer (> 100 µg/ ml) fjernes dog mindre mængder MPAG.
However, at high MPAG plasma concentrations (> 100  g/ ml), small amounts of PAG are removed.
40% lavere sammenlignet med den sene posttransplantationsperiode (3 – 6 måneder efter transplantationen).
In the early post-transplant period (< 40 days post-transplant), renal, cardiac and hepatic transplants patients had mean MPA AUCs approximately 30% lower and C max approximately 40% lower compared to the late post-transplant period (3 – 6 months post-transplant).
Imidlertid var middel enkelt- dosis MPAG AUC 3- 6 gange højere hos personer med svær nyreinsufficiens end hos personer med let nyreinsufficiens eller normale, sunde personer svarende til den kendte renale udskillelse af MPAG.
However, the mean single dose MPAG AUC was 3 – 6 -fold higher in subjects with severe renal impairment than in subjects with mild renal impairment or normal healthy subjects, consistent with the known renal elimination of MPAG.
Middel plasma MPAG AUC 0- 12 timer var 2- 3 gange højere end hos posttransplantationspatienter uden forsinket transplantatfunktion.
Mean plasma MPAG AUC (0- 12h) was 2 – 3-fold higher than in post-transplant patients without delayed graft function.
22 Børn og unge:
Children and adolescents:
Farmakokinetikken af orale kontraceptiva påvirkedes ikke af samtidig administration af mycophenolatmofetil (se også pkt.
The pharmacokinetics of oral contraceptives were unaffected by co administration of mycophenolate (see also section 4.5).
Et studie om samtidig administration af mycophenolatmofetil (1 g 2 gange daglig) og orale kontraceptiva af kombinationstypen indeholdende ethinylestradiol (0, 02 - 0, 04 mg) og levonorgestrel (0, 05- 0, 15 mg), desogestrel (0, 15 mg) eller gestoden (0, 05 – 0, 10 mg) hos 18 ikke- transplanterede kvinder (som ikke fik andre immunosupresiva) i 3 konsekutive menstruationscykler viste ingen klinisk relevant påvirkning af mycophenolatmofetil på den ovulationshæmmende virkning af de orale kontraceptiva.
A study of the co administration of mycophenolate (1 g BID) and combined oral contraceptives containing ethinylestradiol (0.02 mg to 0.04 mg) and levonorgestrel (0.05 mg to 0.15 mg), desogestrel (0.15 mg) or gestodene (0.05 mg to 0.10 mg) conducted in 18 non-transplant women (not taking other immunosuppressants) over 3 consecutive menstrual cycles showed no clinically relevant influence of mycophenolate on the ovulation suppressing action of the oral contraceptives.
Den i dyre carcinogenicitetsundersøgelser højest testede dosis resulterede i ca.
5.3 Preclinical safety data 24 In experimental models, mycophenolate mofetil was not tumourigenic.
2 - 3 gange den systemiske eksponering (AUC eller Cmax) der er observeret hos nyre transplantationspatienter der fik den anbefalede kliniske dosis på 2 g daglig og 1, 3 - 2 gange den systemiske eksponering (AUC eller Cmax) observeret hos hjerte transplantationspatienter der fik den anbefalede kliniske dosis på 3 g daglig.
The highest dose tested in the animal carcinogenicity studies resulted in approximately 2 – 3 times the systemic exposure (AUC or C max) observed in renal transplant patients as the recommended clinical dose of 2 g/ day and 1.3 – 2 times the systemic exposure (AUC or C max) observed in cardiac transplant patients at the recommended clinical dose of 3 g/ day.
Mycophenolatmofetil havde ingen effekt på fertiliteten hos hanrotter i orale doser op til 20 mg kg - 1 - dag- 1.
Mycophenolate mofetil had no effect on fertility of male rats at oral doses up to 20 mg kg-1 day-1.
Den systemiske eksponering af denne dosis repræsenterer 2 - 3 gange den kliniske eksponering ved den anbefalede kliniske dosis på 2 g daglig til nyre transplanterede patienter og 1, 3 - 2 gange den kliniske eksponering ved den anbefalede kliniske dosis på 3 g daglig til hjerte transplanterede patienter.
The systemic exposure at this dose represents 2 - 3 times the clinical exposure at the recommended clinical dose of 2 g/ day in renal transplant patients and 1.3 – 2 times the clinical exposure at the recommended clinical dose of 3 g/ day in cardiac transplant patients.
I en undersøgelse af fertilitet og reproduktion udført på hunrotter forårsagede orale doser på 4. 5 mg kg- 1 dag- 1 misdannelser (inkl. anophthalmi, agnathi og hydrocephalus) hos det første generationsafkom ved fravær af maternel toksicitet.
In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg kg-1 day-1 caused malformations (including anophthalmia, agnathia and hydrocephaly) in the first generation offspring in the absence of maternal toxicity.
0, 3 gange den kliniske eksponering ved den anbefalede kliniske dosis på 3 g daglig til hjerte transplantationspatienter.
The systemic exposure at this dose was approximately 0.5 times the clinical exposure at the recommended clinical dose of 2 g/ day for renal transplant patients and approximately 0.3 times the clinical exposure at the recommended clinical dose of 3 g/ day for cardiac transplant patients.
Ved teratologiske undersøgelser på rotter og kaniner forekom der føtal resorption og misdannelser hos rotter ved 6 mg kg- 1 dag- 1 (inkl. anophthalmi, agnathi og hydrocephalus) og hos kaniner ved 90 mg kg - 1 dag- 1 (inkl. kardiovaskulære og nyre anomalier, såsom cordis ectopia og ectopiske nyrer og diafragma og umbilical brok) med fravær af maternel toksicitet.
In teratology studies in rats and rabbits, foetal resorptions and malformations occurred in rats at 6 mg kg-1  day-1 (including anophthalmia, agnathia, and hydrocephaly) and in rabbits at 90 mg kg-1 day-1 (including cardiovascular and renal anomalies, such as ectopia cordis and ectopic kidneys, and diaphragmatic and umbilical hernia), in the absence of maternal toxicity.
23 De hæmopoietiske og lymfoide organsystemer var de første primære organer der blev afficeret i de toksikologiske undersøgelser der blev foretaget med mycophenolatmofetil på rotte, mus, hund og abe.
The haematopoietic and lymphoid systems were the primary organs affected in toxicology studies conducted with mycophenolate mofetil in the rat, mouse, dog and monkey.
Gastrointestinale virkninger observeredes hos hunden ved systemiske niveauer lig med eller mindre end det kliniske niveau ved den anbefalede dosis.
Gastrointestinal effects were observed in the dog at systemic exposure levels equivalent to or less than the clinical exposure at the recommended doses.
Mikrokrystallinsk cellulose Povidon K- 30 Magnesiumstearat Croscarmellosenatrium
Microcrystalline cellulose Povidone K-30 Magnesium stearate Croscarmellose sodium 25 Tablet coat:
Hypromellose (HPMC 2910) Titandioxid (E171) Macrogol (PEG 400) Talcum Indigocarmin (E 132) Jernoxid, sort (E172) Jernoxid, rød (E172)
Hypromellose (HPMC 2910) Titanium dioxide (E171) Macrogol (PEG 400) Talc Indigo carmine aluminium lake (E132) Iron oxide black (E172) Iron oxide red (E172)
Transparent PVC/ PVdC- aluminium blister i pakningsstørrelser af 50 eller 150 tabletter pr. karton.
Transparent PVC/ PVdC-aluminium blisters in pack sizes of 50 or 150 tablets per carton.
Da mycophenolatmofetil har demonstreret fosterbeskadigende virkning på rotter og kaniner, må Mycophenolate mofetil Teva filmovertrukne tabletter ikke knuses.
Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbit, Mycophenolate mofetil Teva film-coated tablets should not be crushed.
EU/ 07/ 1/ 439/ 003 (50 tabletter) EU/ 07/ 1/ 439/ 004 (150 tabletter)
EU/ 1/ 07/ 439/ 003 (50 tablets) EU/ 1/ 07/ 439/ 004 (150 tablets)
Yderligere information om dette lægemiddel er tilgængelig på Det europæiske Lægemiddelagenturs (EMEAs) hjemmeside http: // www. emea. europa. eu
26 Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
FREMSTILLERE ANSVARLIG FOR BATCHFRIGIVELSE
MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
FREMSTILLER( E) ANSVARLIGE FOR BATCHFRIGIVELSE
MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
Navn og adresse på fremstiller( ne) ansvarlig for batchfrigivelse
Name and address of the manufacturer responsible for batch release
TEVA Pharmaceutical Works Private Limited Company Pallagi út 13 Debreccen H- 4042 Hungary
Debrecen H-4042 Hungary
TEVA Pharmaceutical Works Private Limited Company H- 2100 Gödöllő Táncsics Mihály út 82 Hungary (Hovedkvarter::
TEVA Pharmaceutical Works Private Limited Company H-2100 Gödöllő Táncsics Mihály út 82 Hungary
Swensweg 5 2031 GA Haarlem Holland
Swensweg 5 2031 GA Haarlem The Netherlands
Pharmacovigilance system Indehaveren af markedsføringstilladelsen skal sikre at pharmacovigilancesystemet, som er beskrevet i udgave 2. 0 dateret september 2006 findes i Module 1. 8. 1 i ansøgningen om markedsføringstilladelse, er på plads og fungerer før og medens produktet er på markedet.
Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 2.0, dated September 2006 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.
27 Risikostyringsplan Ansøgeren har ikke fremsendt en Risikostyringsplan.
29 Risk Management Plan No description of Risk Management Plan has been provided by the applicant.
Da denne ansøgning vedrører et generika baseret på et referencelægemiddel, for hvilket der ikke er blevet identificeret nogen sikkerhedsanliggender, der kræver yderligere risikominimeringsaktiviteter, er denne fremgangsmåde acceptabel.
Since the application concerns a generic with a reference medicinal product for which no safety concern requiring additional risk minimisation activities has been identified this approach is considered acceptable.
PSURs Den fastsatte plan for indsendelse af PSUR for begge styrker, skal følge den fastsatte plan for indsendelse af PSUR for reference lægemidlet.
PSURs The PSUR submission schedule for both strengths should follow the PSUR schedule for the reference products.
28 BILAG III
30 ANNEX III
ETIKETTERING
31 A. LABELLING
30 OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE
32 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
100 kapsler 300 kapsler
100 capsules 300 capsules
32 MINDSTEKRAV TIL OPLYSNINGER PÅ BLISTERKORT ELLER BLISTERSTRIPS
34 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
33 OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE
35 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
50 tabletter 150 tabletter
50 tablets 150 tablets
34 Ikke anvendte lægemidler samt affald heraf bør destrueres i henhold til lokale retningslinier.
Any unused product or waste material should be disposed of in accordance with local requirements.
35 MINDSTEKRAV TIL OPLYSNINGER PÅ BLISTERKORT ELLER BLISTERSTRIPS
37 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
INDLÆGSSEDDEL
38 B. PACKAGE LEAFLET
37 INDLÆGSSEDDEL:
39 PACKAGE LEAFLET:
Mycophenolate mofetil Teva 250 mg kapsler, hårde Mycophenolatmofetil
Mycophenolate mofetil Teva 250 mg hard capsules Mycophenolate mofetil
- Lægen har ordineret Mycophenolate mofetil Teva til dig personligt.
- This medicine has been prescribed for you.
Mycophenolate mofetil Tevas virkning og hvad du skal bruge det til 2.
What Mycophenolate mofetil Teva is and what it is used for 2.
Det skal du vide, før du begynder at tage Mycophenolate mofetil Teva 3.
Before you take Mycophenolate mofetil Teva 3.
Sådan skal du tage Mycophenolate mofetil Teva 4.
How to take Mycophenolate mofetil Teva 4.
Sådan opbevarer du Mycophenolate mofetil Teva 6.
How to store Mycophenolate mofetil Teva 6.
MYCOPHENOLATE MOFETIL TEVAS VIRKNING OG HVAD DU SKAL BRUGE DET TIL
WHAT MYCOPHENOLATE MOFETIL TEVA IS AND WHAT IT IS USED FOR
Det anvendes sammen med anden medicin med tilsvarende virkning (inklusive ciclosporin og binyrebarkhormon).
It is used in combination with other medicines with a similar function (i. e. ciclosporin and corticosteroids).
DET SKAL DU VIDE, FØR DU BEGYNDER AT TAGE MYCOPHENOLATE MOFETIL TEVA
BEFORE YOU TAKE MYCOPHENOLATE MOFETIL TEVA
Tag ikke Mycophenolate mofetil Teva:
Do not take Mycophenolate mofetil Teva
- Hvis du er overfølsom (allergisk) over for mycophenolatmofetil, mycophenolsyre eller et af
- if you are allergic (hypersensitive) to mycophenolate mofetil, mycophenolic acid or any of the
de øvrige indholdsstoffer i Mycophenolate mofetil Teva.
other ingredients of Mycophenolate mofetil Teva.
- Hvis du ammer.
- if you are breast-feeding.
Du bør straks informere din læge:
Take special care with Mycophenolate mofetil Teva You should inform your doctor immediately:
- Hvis du oplever nogen form for tegn på infektion (f. eks. feber, ondt i halsen), uventede blå
- if you experience any evidence of infection (e. g. fever, sore throat), unexpected bruising and/ or
mærker og/ eller blødning.
bleeding
- Hvis du har eller nogensinde har haft problemer med dit fordøjelsessystem, feks. mavesår
- if you have or ever have had any problems with your digestive system, e. g. stomach ulcers
Mycophenolate mofetil Teva nedsætter din organismes forsvarsmekanismer.
Mycophenolate mofetil Teva reduces your body’ s defence mechanism.
Derfor skal du begrænse din udsættelse for sollys og ultraviolet (UV) lys ved hjælp af beskyttende beklædning og solblokker med høj beskyttelsesfaktor.
Therefore you should limit your exposure to sunlight and ultra violet (UV) light by wearing appropriate protective clothing and using a sunscreen with a high protection factor.
- Tager du nogen form for medicin, som indeholder: azathioprin eller andre stoffer der
- Are you taking any medicines containing: azathioprine or other immunosuppressive agents (which
nedsætter immunforsvaret (som undertiden gives til patienter efter en transplantationsoperation), colestyramin (som bruges til behandling af patienter med for højt kolesteroltal), rifampicin (antibiotika), mavesårsmedicin, phosphatbindere (bruges til patienter med kronisk nyresvigt for at reducere absorptionen af phosphat) eller anden medicin (inklusive håndkøbsmedicin), som din læge ikke er bekendt med?
are sometimes given to patients after a transplant operation), cholestyramine (used to treat patients with high blood cholesterol), rifampicin (antibiotic), antacids, phosphate binders (used in patients with chronic renal kidney failure to reduce the absorption of phosphate) or any other medicines (including those you can buy without a prescription) that your doctor does not know about?
bruge.
indicated for you
Indtagelse af mad og drikkevarer har ingen indflydelse på din behandling med Mycophenolate mofetil Teva.
Taking Mycophenolate mofetil Teva with food and drink Taking food and drink has no influence on your treatment with Mycophenolate mofetil Teva.
Tag ikke Mycophenolate mofetil Teva, hvis du ammer.
Pregnancy and breast-feeding Do not take Mycophenolate mofetil Teva if you are breast-feeding.
Du skal bruge prævention før, mens og i 6 uger efter at du er ophørt med at tage Mycophenolate mofetil Teva.
Your doctor should advise you about using contraception before taking Mycophenolate mofetil Teva, whilst taking Mycophenolate mofetil Teva, and for 6 weeks after you have stopped taking Mycophenolate mofetil Teva.
Mycophenolate mofetil Teva kan måske forårsage spontane aborter eller skade dit ufødte barn, herunder give problemer med udviklingen af ørerne.
Mycophenolate mofetil Teva may cause spontaneous abortions or damage, including problems with development of the ears, to your unborn baby.
Du skal straks fortælle din læge det, hvis du er blevet gravid, ammer, eller hvis du bliver eller påtænker at blive gravid i den nærmeste fremtid.
Tell your doctor straight away if you are pregnant, breast-feeding, become pregnant or plan to start a family in the near future.
Det er ikke påvist, at Mycophenolate mofetil Teva påvirker evnen til at føre bil eller betjene maskiner.
Driving and using machines Mycophenolate mofetil Teva has not been shown to impair your ability to drive or operate machines.
SÅDAN SKAL DU TAGE MYCOPHENOLATE MOFETIL TEVA
HOW TO TAKE MYCOPHENOLATE MOFETIL TEVA
Den sædvanlige dosis er:
The usual way to take Mycophenolate mofetil Teva is as follows:
Den anbefalede dosis er 600 mg/ m² to gange daglig.
The recommended dose is 600 mg/ m2 taken twice a day.
Mycophenolate mofetil Teva bør ikke anvendes til hjertetransplanterede børn og unge, da der ikke er tilgængelig data til at anbefale dette.
No data are available to recommend the use of Mycophenolate mofetil Teva in children and adolescents who have received a heart transplant.
39 Levertransplantation
Liver Transplant
Den første dosis Mycophenolate mofetil Teva til indtagelse gennem munden gives tidligst 4 dage efter transplantationen, og når du er i stand til at indtage medicin gennem munden.
41 The first dose of oral Mycophenolate mofetil Teva will be given to you at least 4 days after the transplant operation and when you are able to swallow oral medicines.
Mycophenolate mofetil Teva bør ikke anvendes til levertransplanterede børn og unge, da der ikke er tilgængelig data til at anbefale dette.
No data are available to recommend the use of Mycophenolate mofetil Teva in children and adolescents who have received a liver transplant.
Anvendelsesmåde og indgivelsesvej Synk kapslerne hele med et glas vand.
Method and route of administration Swallow your capsules whole with a glass of water.
Det er vigtigt ikke at indtage for mange kapsler.
If you take more Mycophenolate mofetil Teva than you should It is important not to take too many capsules.
Hvis du på noget tidspunkt glemmer at tage medicinen, skal du tage den, så snart du kommer i tanke om det.
If you forget to take Mycophenolate mofetil Teva If you forget to take your medicine at any time, take it as soon as you remember, then continue to take it at the usual times.
Stop ikke med at tage Mycophenolate mofetil Teva, bare fordi du måtte få det bedre.
If you stop taking Mycophenolate mofetil Teva Do not stop taking Mycophenolate mofetil Teva because you feel better.
Kontakt din læge, hvis du har yderligere spørgsmål.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Mycophenolate mofetil Teva kan som al medicin give bivirkninger, men ikke alle får bivirkninger.
Like all medicines, Mycophenolate mofetil Teva can have side effects, although not everybody gets them.
Meget almindelige bivirkninger (det forekommer hos flere end l ud af 10 behandlede): • Diarre, opkastning, føle sig syg. • Fald i det normale indhold af forskellige blodceller, hvilket kan resultere i en øget risiko for infektioner, blå mærker, blødninger, kortåndethed og svaghed. • Bakterie -, svampe - og virusinfektioner i fordøjelseskanalen og urinrøret, forkølelsessår og helvedesild.
Very common side effects likely to affect more than 1 in 10 people:  Diarrhoea, vomiting, feeling sick  Decrease in normal amounts of different blood cells, which can result in increased risk of infections, bruising, bleeding, breathlessness and weakness  Bacterial, fungal and viral infections of the digestive and urinary tract, cold sores and shingles